Helping you make wiser investment decisions

Lilly and Boehringer's Jardiance, trailing AZ's Farxiga in chronic kidney disease, posts early efficacy win

March 16, 2022 fkansteiner



Lilly and Boehringer’s Jardiance, trailing AZ’s Farxiga in chronic kidney disease, posts early efficacy win
fkansteiner
Wed, 03/16/2022 – 10:27



Source link